You are here

Sterculic Acid Analogs to Inhibit Macular Degeneration

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43EY024202-01
Agency Tracking Number: R43EY024202
Amount: $224,700.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NEI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
BOX 8175
NEW HAVEN, CT 06530-0175
United States
DUNS: 142406110
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ALAN SUTHERLAND
 (203) 494-5288
 asutherland@L2dx.com
Business Contact
 MARTIN MATTESSICH
Phone: (203) 494-5288
Email: mmattessich@L2dx.com
Research Institution
 Stub
Abstract

ABSTRACT The long-term product goal of this project is a small molecule therapeutic for choroidal neovascularization (CNV, the hallmark of wet age-related macular degradation), an abnormal growth of blood vessels in the choroid layer of the eye that results in damage to the retina and consequent blindness. Our lead compound is the natural product sterculic acid, which has been shown to inhibit CNV in animal models. The main current treatment options for CNV involves intravitreal injection of anti-VEGF agents such as ranibizumab (Lucentis), aflibercept (Eylea) and (in off-label use) bevacizumab (Avastin) which, while often slowing disease progression, have a number of side-effects associated with the method of administration. A small molecule therapeutic which might be administered topically would present obvious advantages. Sterculic acid has very recently been shown to mitigate the induction of CNV in a rat model and to antagonize the inflammatory effects of 7- ketocholesterol (7KCh) in cultured human re

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government